Schrdinger, Inc. (SDGR) said Monday it has entered into a multi-year discovery collaboration with Bristol Myers Squibb Co. (BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.
Under the collaboration, Schrdinger's will combine its physics-based computational platform and drug discovery capabilities with Bristol Myers Squibb's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.